

Peter Tugwell, Co-ordinating Editor Representative, Cochrane Collaboration Steering Group; Co-ordinating Editor, Editor, Cochrane Musculoskeletal Group

Peter Tugwell has received travel and research support from dozens of pharmaceutical firms (PFs) for over thirty years. This support has permitted research associates to work on methodological projects of no commercial interest, has supported students and fellows who otherwise would not have been able to get an education, and has provided partial support for the planning and organization of scientific meetings in which the funder had no say about subject matter, content, or speakers. He has never received personal salary research support or awards from PFs. He was principal investigator for randomized trials of cyclosporine published in the Lancet and NEJM; these were funded in part but never in whole by PFs who had no access to the emerging data, no control over whether or when the studies stopped, and no veto power over any publications or presentations. While Chair of Medicine at the University of Ottawa, Peter prohibited PFs from solo support of department educational rounds or from any say in content. He also enforced a policy of using generic names. When he served on the US Government National Science Panel examining the relationship between silicone breast implants and connective tissue disorders, he was certified by a U.S. District Court Judge to be free of any industry influence. Prior to 2005, the Musculoskeletal Collaborative Review Group has received unrestricted grants for staff support in carrying out systematic reviews, a number of which failed to draw favorable conclusions about donor's drugs. Since the decision to prohibit industry funding in 2005 the Musculoskeletal Group has not received any funding in support of any systematic reviews.

Rachelle Buchbinder, Co-ordinating Editor, Australian Editorial Base, Cochrane Musculoskeletal Group

Rachelle Buchbinder has received some travel and research support from pharmaceutical firms (PFs) over the last 20 years. This support has primarily been limited to travel to several scientific meetings for the purpose of education or permitted research on investigator-initiated projects. With respect to the latter, the PFs have had no control over the design or management of the studies and no access to the emerging data and no veto power over any publications or presentations. She has also been involved in many PF-sponsored multi-centred trials as part of study site personnel but has had no direct intellectual input into these studies and has not received any personal salary support for her involvement in these trials. She has acted as a paid consultant for one PF in relation to advice about one drug and preparation of a submission to the Australian Pharmaceutical Benefits Advisory Committee (PBAC). She was a member of the Economic Subcommittee of the Australian PBAC from 1997-2003 and currently acts as an advisor to the Monash Evaluation Group who is responsible for evaluating some of the submissions to the Australian PBAC.

Rob de Bie, Editor, Cochrane Musculoskeletal Group

Rob de Bie, has until now never received grants or money from the pharmaceutical industry for his own use, nor received a personal salary from the industry. His research has in part been

sponsored by the industry, but always under University Contracts claiming independence of the researcher and the right to publish results, irrespective the outcome of the research. As an advisory board member for several government and industry organizations, he only receives travel allowances, which are passed through the university administration. Surpluses are always directly transferred to the musculoskeletal profit center, maintained by the Care And Public Health Research Institute, to be of benefit for research projects.

Angela Busch, Editor, Cochrane Musculoskeletal Group

Angela Busch is employed by a university and to date her research has had no commercial component. She has not received grants or money from industry (i.e., pharmaceutical firms, companies manufacturing or marketing health products, or companies supplying services).

Ann Cranney, Editor, Cochrane Musculoskeletal Group

Ann Cranney has received speaker/consultant fees and research support from a few different pharmaceutical funds over the last 10 years. This funding has been in the area of osteoporosis (Merck, Eli Lilly, Aventis, Novartis) and the funds have been used primarily to fund research coordinators. These research grants have not been used for personal salary support. She did not receive direct support from industry for the Cochrane systematic reviews of osteoporosis that have been completed.

Robin Christensen, Statistical Editor (Australian Editorial Base), Cochrane Musculoskeletal Group

Robin Christensen has received travel and research support from a few pharmaceutical firms (PF) over the last 5 years. This support has enabled him to participate in rheumatology-related congresses, and to elaborate statistical/methodological reports of no commercial interest. He has never received personal salary, research support or awards from PFs related to products; he has been invited speaker for companies and institutions as a statistical expert (i.e. ranking/interpretation of available data in relation to evidence-based medicine), in which the funder had no say about subject matter or content.

Peter Juni, Editor, Cochrane Musculoskeletal Group

Peter Juni has not done any consulting work for or received grants from any commercial bodies.

Anne Lyddiatt, Editor, Cochrane Musculoskeletal Group

Anne Lyddiatt is the national trainer for the Patient partner in Arthritis program. This program is funded by an unrestricted educational grant from the primary investigator and her expenses related to travel are covered and she receives a yearly honorarium.

Anne Rutjes, Editor, Cochrane Musculoskeletal Group

Anne Rutjes has until now never received grants or money from the pharmaceutical industry, nor received a personal salary from the industry. The only exception is the financial support she received to cover printing costs of her PhD thesis, which came from several pharmaceutical companies (Astellas Pharma Europe, Roche Diagnostics Nederland B.V., Sanofi-Aventis, Bristol-Myers Squibb, Zambon Nederland B.V.), but also from non-profit organizations (Stichting tot bevordering van de Klinische Epidemiologie, Stichting Amstol, J.E. Jurriaanse Stichting, University of Amsterdam, Dutch Cochrane Center) and Kleijnen Systematic Reviews Ltd. Her research has in part been sponsored by the non-profit organizations, such as NCI, ZONMW and SNF, but always under contracts claiming independence of the researcher and the right to publish results, irrespective of the outcome of the research.

Beverley Shea, Editor, Cochrane Musculoskeletal Group

Beverley Shea collaborates on multiple systematic reviews with the Musculoskeletal Collaborative Review Group who has received unrestricted grants for staff support in carrying out systematic reviews. She is currently employed by a non-governmental organization who received funding from international research and charity organizations

Maria Suarez-Almazor, Editor, Cochrane Musculoskeletal Group

Maria Suarez-Almazor has received limited travel assistance, research support and consulting fees from several different pharmaceutical firms (PFs) in the past ten years. The research and consulting work performed has been of no commercial interest, and mostly related to methodological issues such as measurement of quality of life, and not to clinical trials, or effectiveness studies for a particular drug. The PF covering these activities had no participation in any developmental work performed by Dr. Suarez-Almazor. The PFs did not review any data or results before presentation to peers or publication, and had no veto power on these.

George Wells, Statistical Editor, Cochrane Musculoskeletal Group

George Wells has received travel and research support from a few different pharmaceutical firms (PF) over the last 20 years. This support has permitted research associates to work on methodologic projects of no commercial interest, and has supported students. He has never

received personal salary research support or awards from PFs. He has been an investigator for randomized trials sponsored and co-sponsored by PFs.

Tania Winzenberg, Editor, Cochrane Musculoskeletal Group

Tania Winzenberg has only received travel support for conference travel from pharmaceutical firms indirectly in the form of travel grants made by conference organising bodies. She has been involved in PF-sponsored multi-centred trials as part of study site personnel but has had no direct intellectual input into these studies and has not received any personal salary support for her involvement in these trials.

Gustavo Zanoli, Editor, Cochrane Musculoskeletal Group

Gustavo Zanoli has received travel and research support from several competing pharmaceutical firms and implant manufacturers (*companies*), as well as from public and private funding agencies (*institutions*) for over 10 years. This support has contributed partly to the University salary, has permitted research on methodological projects of no commercial interest, and has provided partial support for the planning and organization of scientific meetings in which the funder had no say about subject matter, content, or speakers. He has been local investigator for randomized trials and observational studies funded by companies and institutions. He has been invited speaker for companies and institutions at conferences where the funder had no say about subject matter or content. As chair of evidence-based working groups, has accepted unrestricted support from companies and institutions for logistical projects (i.e. websites) or publications (printing) in which the funder had no say about subject matter or content.